Journal article
Hereditary cancer risk assessment and genetic testing in the community urology practice setting
The Prostate, v 82(7), pp 850-857
01 May 2022
PMID: 35239202
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Abstract Objectives To evaluate the feasibility of integrating a hereditary cancer risk assessment (HCRA) process in the community urology practice setting for patients with prostate cancer (PCa). Methods In this prospective intervention, an HCRA process was implemented across six different community urology clinics between May 2019 and April 2020. The intervention included a process integration during which the workflow at each site was refined, a post‐integration period during which HCRA was conducted in all patients with PCa, and a follow‐up period during which healthcare providers and patients reported their satisfaction with the HCRA and genetic testing process. Results Among patients who completed a family history assessment during the post‐integration period, 23.6% met guideline criteria for genetic testing. Of all patients seen at the clinic during the post‐integration period, 8.7% completed genetic testing; this was a twofold increase over the period immediately preceding process integration (4.2%), and a sevenfold increase over the same period 1 year prior (1.2%). The majority of providers reported that the HCRA was as important as other regularly performed assessments (61.0%) and planned to continue using the process in their practice (68.3%). Most patients believed that the genetic test results were important for their future cancer care (84.7%) and had already shared their test results with at least one family member (63.2%). Conclusions This study demonstrated that implementing an HCRA process in the community urology practice setting was feasible, generally favored by providers and patients, and resulted in an increase in the number of patients with PCa who completed genetic testing.
Metrics
6 Record Views
1 citations in Scopus
Details
- Title
- Hereditary cancer risk assessment and genetic testing in the community urology practice setting
- Creators
- Neal D. Shore - Carolina Urologic Research CenterLauren Lenz - Myriad GeneticsElizabeth S. Cogan - Myriad GeneticsDiana Iliev - Myriad GeneticsLizzie Spencer - Myriad GeneticsDarl D. Flake - Myriad GeneticsStephanie Meek - Myriad GeneticsThaylon Davis - Myriad GeneticsKaren Copeland - Myriad GeneticsRobert Finch - Myriad GeneticsWilliam Schiff - Urology AssociatesHoward Korman - Comprehensive UrologyManoj Rao - Urologic Specialists of Northwest Indiana Merrillville Indiana USALaurence Belkoff - MidLantic Urology Bala Cynwyd Pennsylvania USAMark Jalkut - Associated Urologists of North Carolina Raleigh North Carolina USANeil Mariados - Associated Medical Professionals Syracuse New York USARichard D'Anna - Arkansas Urology Little Rock Arkansas USABryan Mehlhaff - Oregon Urology InstituteThomas P. Slavin - Myriad GeneticsTodd D. Cohen - Myriad Genetics
- Publication Details
- The Prostate, v 82(7), pp 850-857
- Publisher
- Wiley
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:000763555500001
- Scopus ID
- 2-s2.0-85125546411
- Other Identifier
- 991021916911004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Endocrinology & Metabolism
- Urology & Nephrology